Galaxy Diagnostics offers a comprehensive toolkit for detecting stealth pathogens. Whether you’re treating suspected Lyme Borreliosis, Bartonellosis, or Babesiosis, we help you move from diagnostic uncertainty to clinical action, faster and with more confidence.
Lyme Borrelia Direct Detect: Nanotrap®
Provides direct detection of Borrelia OspA antigen from urine, enabling earlier diagnosis in acute cases³ and confirms presence of pathogen in patients with a history of Lyme disease, even when the immune response is absent or suppressed.
Tests: BBB Direct Detect + Bartonella IgG Detect
Digital PCR + 4-Species Bartonella IFA Serology*
By combining culture-enriched Digital PCR with species-specific antibody detection, Galaxy provides DNA-level confirmation⁴ ⁵ and immune response insights across the four Bartonella species most associated with human disease, offering a more complete diagnostic picture than either method alone.
Improved diagnostic certainty, with combined tests and a complete 3-day draw which leads to more confident decisions and better patient outcomes.
*Direct detection (dPCR) for Bartonella, Borrelia, and Babesia
*Culture and IFA testing available exclusively for Bartonella
*BBB is a multi-plexed direct test and will also include Babesia and Borrelia
BBB Direct Detect +
Bartonella IgG IFA
BBB Direct Detect + Lyme Borrelia Direct Detect
Direct evidence of pathogen presence (DNA and antigen) supports precise and targeted treatment plans
Immune system insight via IFA, supporting diagnostic confidence, tracking treatment response, and providing a full clinical picture for Bartonella
Genus-level detection, expanding clinical awareness beyond species-limited tests
Improved diagnostic certainty, with combined tests and a complete 3-day draw leading to more confident decisions and better patient outcomes
Quick and simple registration process to access our complete testing services.
Choose in-clinic use or drop-ship delivery direct to your patient, based on your workflow.
Access results via our portal, plus guidance from our clinical team when needed.
What are Galaxy's main test offerings?
Three platforms anchor the menu: the BBB Direct Detect digital PCR assay (direct, genus-level molecular detection of Bartonella, Borrelia, and Babesia from whole blood, with Bartonella-specific culture enrichment); the Bartonella IgG Detect IFA (indirect serology measuring immune exposure to four clinically relevant Bartonella species in North America); and the Lyme Borrelia Direct Detect Nanotrap urine antigen test (direct detection of OspA). These test offerings are available individually and in bundled 1-day and 3-day panels.
Why not just rely on standard two-tier Lyme serology (STTT/MTTT)?
Two-tier serology is indirect: it provides supportive evidence of exposure, not of pathogen presence, and a single EIA or immunoblot alone yields false positives and negatives, which is why two tiers are required. It also underperforms early: only about 30% of acute patients present with an erythema migrans rash, and roughly half of those test serologically negative at that stage. Direct antigen and direct molecular methods can provide evidence before or during seroconversion, complementing the delayed and variable antibody response.
Which Bartonella species does the IFA cover, and why those four?
The Bartonella IgG Detect IFA reports individual titers for B. henselae, B. vinsonii berkhoffii, B. koehlerae, and B. quintana, the four species most associated with human infection in North America. Galaxy is one of the few commercial labs to include B. koehlerae, an omission on many other panels that can cause missed exposures.
When will results be available, and how do we access them?
Typically two to three weeks, three weeks specifically for anything involving the BBB Direct Detect, because of its added week-long culture period. There’s no login needed to place an order; a portal password-setup prompt is sent automatically once the first sample reaches the lab. Results can also be faxed on request, though they’re posted to the portal (Dendi) either way.
Why might these infections show up in patients with neuropsychiatric or chronic-fatigue presentations?
A growing body of literature links Bartonella and Babesia to neuropsychiatric and chronic-fatigue presentations, including schizophrenia and adult psychosis case-control work, mild cognitive impairment, pediatric acute-onset neuropsychiatric syndrome, and ME/CFS-consistent illness. The proposed mechanisms include direct endothelial or CNS invasion and immune-mediated inflammation. These associations are why a vector-borne workup can be warranted in otherwise treatment-refractory neuropsychiatric or fatigue syndromes, though causation remains under active study.
Get started with direct pathogen detection for Bartonella, Borrelia, and Babesia, built for the complex cases standard testing has already missed.
